In November 2021, Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader, together with UNGCNI launch a national initiative for improving early access to treatment for Rare Disease Patients in India.
The joint rare disease initiative took charge of addressing the challenges to ensure access to treatment for rare disease patients waiting on the crowdfunding portal in an integrated manner.
Through the initiative, 300+ PSUs and Corporate leaders were reach, which has help to generate a pool of insights and recommendations that will help in shaping the future of access to rare disease treatment in the country.
The 6-months intensive initiative has been able to bring together stakeholder groups (private sector, PSUs, corporate giants, etc.) that can support mobilizing and operationalizing funding for the rare disease under CSR grants and donations for strengthening the existing crowdfunding mechanism and pathways set in the India Rare Disease Policy.
Furthermore, it has created the roadmap for addressing rare disease funding requirements in alignment with the Government policies and guidelines Ministry of Corporate Affairs, Department of Public Enterprises, and Ministry of Health and Family Welfare, Govt of India.
The eminent experts from public and private sector organizations participated in the initiatives including MoHFW, AIIMS (New Delhi), Kerala State Legal Services Authority (KELSA), CoEs (SGPGI, Lucknow, KEM, Mumbai, SSKM, Kolkata), and 24 PSUs and Corporate Leaders (e.g., BHEL, Bharat Petroleum, ONGC etc).
Mr. Aseem Kumar, Officiating Executive Director, UNGCNI Said :
Ms. Serina Fischer, General Manager, Takeda India Said :
Dr. Ruchi Sogarwal, Head-Public Affairs & Patient Advocacy, Takeda India Said :
Mr. Ajeet Kumar Sharma, AGM, Bharat Heavy Electricals Ltd. & Secretary, UNGCNI Said :
Dr. Somnath Singh, Programme Manager, UNGCNI, Said :
About UNGCNI
Global Compact Network India (GCNI), the Indian Local Network of the United Nations Global Compact (UNGC), New York is the first Local Network globally to be establish with full legal recognition.
As the UNGC local arm, GCNI has been acting as a country level platform in providing a robust platform for Indian businesses, academic institutions and civil society organizations to join hands for strengthening responsible business practices.
Our ‘10 Principles in areas of Human Rights, Labour, Environment and Anti-corruption’ provide a common ethical and practical Framework for Corporate Responsibility – and the 17 ‘Sustainable Development Goals (SDGs)’ adopted in September 2015, by all 195 Member States of the United Nations including India in order to end extreme poverty, fight inequality and injustice, and protect our planet- understood and interpreted by businesses around the world, regardless of size, complexity or location.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.
Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI).
We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.
Our employees are commit to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.